Wegovy questions answered: the FAQs, with sources

Key takeaways

• About 15 percent, then a plateau. On semaglutide 2.4 mg, mean weight loss was 15.2 percent at 104 weeks versus 2.6 percent on placebo, and it flattens out around week 60, so the stall near month 15 is expected, not a failure .
• Side effects are common but mostly mild. Nausea hits about 44 percent, diarrhea 30 percent, vomiting 24 percent, and constipation 24 percent, all far above placebo . In the tolerability analysis 98.1 percent of gut events were mild or moderate and they cluster during dose escalation, then fade .
• Stopping means regaining. A year after stopping 2.4 mg, patients regained about two-thirds of the weight (11.6 percentage points), and the net fell from 17.3 percent down to 5.6 percent . Staying on kept it off: continuing lost a further 7.9 percent while switching to placebo regained 6.9 percent .
• Wegovy is no longer the strongest shot. Head to head, tirzepatide beat it at 72 weeks (20.2 percent versus 13.7 percent) , a 7.2 mg high dose now reaches about 20.7 percent , and a 25 mg oral pill is on the market .
• Cheap compounded copies are largely over. The FDA declared the semaglutide shortage resolved in February 2025 and compounding an essentially-a-copy version is no longer permitted . Self-pay through the maker runs about 349 dollars a month against a roughly 1,349 dollar list price .

Skip to:

• The short version and where Wegovy sits
• How much weight, and why it stalls
• The side effects by the numbers, and how to blunt them
• The rare red flags, in context
• Dosing: the ramp, staying low, and missed shots
• What happens when you stop
• Alternatives, cost, and compounded
• Living on it: muscle, food noise, alcohol, pregnancy
• The bottom line

The short version and where Wegovy sits

How much weight, and why it stalls

The honest headline number is about 15 percent. In STEP 5, the two-year trial of the 2.4 mg dose, mean weight loss was 15.2 percent at 104 weeks versus 2.6 percent on placebo, and roughly a third of people (36.1 percent) lost 20 percent or more, against 2.3 percent on placebo . That is a big effect, but it is an average: some people lose far more, some far less, and none of it is linear.

The plateau that fills Reddit threads is built into the drug, not a sign you did something wrong. In the same trials, weight loss flattened out around week 60 and was then maintained, not reversed, for as long as people kept dosing . So hitting a wall near month 15 is the expected shape of the curve. Chasing it with crash dieting on top of an appetite suppressant is how people lose muscle and stall harder. The mechanism, and what actually restarts progress, is in why GLP-1 weight loss plateaus.

The side effects by the numbers, and how to blunt them

Gut side effects are the rule, not the exception, and the label puts real numbers on them. The reason they are tolerable for most people is timing: they are worst while you are climbing the dose ladder and settle as your body adjusts.

Here is the part the percentages hide: 98.1 percent of these gut events were mild or moderate, they were most prevalent during or shortly after a dose step, and people typically recovered within a few days . The single most effective lever is a slower ramp. The label lets you stay four extra weeks at a lower dose if a step is rough, and the tolerability analysis explicitly found that gradual escalation helps . Smaller meals, less fat and fried food, and not eating to full also cut nausea. The full playbook is in what actually helps GLP-1 side effects.

Constipation gets its own mention because it is the one people underrate and it is fixable without a doctor. At 24 percent it is as common as vomiting . The drug slows the whole gut, so the fix is mechanical: water first (you are eating and drinking less, so you are quietly dehydrated), then daily fiber, movement, and a cheap osmotic laxative like polyethylene glycol if that is not enough. Do not wait a week to act; catching it early is far easier than clearing an impaction.

Two other complaints have easy angles. The sulfur or rotten-egg burps have a food fix, covered in what to eat for GLP-1 sulfur burps. And the shedding that shows up a few months in is mostly telogen effluvium from rapid weight loss, not the drug attacking your follicles, explained in why GLP-1 hair loss happens.

The rare red flags, in context

A handful of risks are serious but uncommon, and the point of listing them is knowing what to watch for, not talking yourself out of the drug. Take them once, plainly.

• Thyroid C-cell tumors: the boxed warning. Semaglutide caused these in rodents in a dose- and duration-dependent way; whether it does so in humans is unknown, and it is contraindicated if you or a close relative have medullary thyroid carcinoma or MEN 2 syndrome . Human causation is not established. If that family history does not apply to you, this is a labeling flag, not a personal alarm.
• Acute pancreatitis: rare (0.2 cases per 100 patient-years in trials) but real; sudden severe upper-abdominal pain that bores into the back means stop dosing and get evaluated .
• Gallbladder disease: rapid weight loss raises gallstone risk, and gallstones (cholelithiasis) hit 1.6 percent on Wegovy versus 0.7 percent on placebo . Right-upper-abdomen pain after fatty meals is the tell.
• Kidney injury from dehydration: the mechanism is boring and preventable. Vomiting and diarrhea dry you out, and dehydration is what actually hurts the kidneys . Drink through the nausea; that one habit covers most of this risk.

Dosing: the ramp, staying low, and missed shots

The standard ramp is 0.25 mg weekly for four weeks, then 0.5, 1, and 1.7 mg at four-week steps, up to a 2.4 mg maintenance dose . That slow climb is not caution theater; it is what keeps the gut side effects mild, and you are allowed to hold a step longer if you need to .

Can you stay on a lower dose? Yes, and it is on the label: the sanctioned maintenance is either 2.4 mg (recommended) or 1.7 mg once weekly . If 2.4 mg is punishing and 1.7 mg holds your weight, 1.7 mg is a legitimate place to live, not a compromise you have to hide. If you miss a shot, the rule is simple: if your next scheduled dose is more than two days away, take the missed one as soon as you can; if it is less than two days away, skip it and resume on your normal day .

For people reconstituting and drawing their own, the mL-to-mg-to-units math is where mistakes happen, so run the numbers with the free GLP-1 ramp planner and read reconstitution and titration risk; rotating injection sites matters too, per injection-site rotation and skin.

There is also a stronger shot now. In March 2026 the FDA approved Wegovy HD, a 7.2 mg dose that reached about 20.7 percent mean weight loss in the STEP UP trial, for people who have already tolerated 2.4 mg for at least four weeks and need more . It is not a starting dose; it is the next rung if the standard maintenance stops delivering.

What happens when you stop

This is the answer Reddit least wants to hear, and the data is blunt about it. Wegovy manages weight while you take it; it does not reset your set point. In the STEP 1 extension, a year after stopping 2.4 mg, participants regained about two-thirds of what they had lost (11.6 percentage points), and the group average fell from a 17.3 percent loss back to 5.6 percent .

The mirror image proves the point. In STEP 4, people who had already ramped up were split at week 20: those who continued 2.4 mg lost a further 7.9 percent, while those switched to placebo regained 6.9 percent, a 14.8 percentage-point gap by week 68 . So maintenance is continued dosing, full stop, and the lower 1.7 mg maintenance dose is often enough to hold ground .

If you are thinking about tapering rather than a hard stop, the tradeoffs are in what happens when you stop a GLP-1 and what GLP-1 microdosing actually is. And it is not all-or-nothing: 48.2 percent still kept at least 5 percent off a year after stopping .

Alternatives, cost, and compounded

If the question is which drug loses the most weight, semaglutide is not the answer anymore. In SURMOUNT-5, the direct head-to-head, tirzepatide reached 20.2 percent at 72 weeks versus 13.7 percent for semaglutide, and more people hit the 20 percent and 25 percent milestones on tirzepatide . The full breakdown is in tirzepatide versus semaglutide, head to head. There is also the needle-free route: a 25 mg oral semaglutide pill was approved in December 2025, with about 16.6 percent loss in the best-case full-adherence analysis, detailed in the Wegovy pill write-up .

On cost, the sticker price and what people actually pay are different planets. Wegovy carries a list price around 1,349 dollars a month, but the maker's self-pay channel runs about 349 dollars a month for the pen (with a 199 dollar introductory offer on the two starter doses through the end of 2026), the 7.2 mg high dose is about 399 dollars, and the oral pill starts near 149 dollars . Those are manufacturer self-pay figures, so treat them as the floor for cash buyers, not a guarantee for your pharmacy.

Is compounded semaglutide still a thing? Mostly not, as a cheap durable option. The FDA declared the semaglutide shortage resolved in February 2025, the courts declined to block the wind-down, and compounding a version that is essentially a copy of the approved drug is no longer legally permitted for either 503A pharmacies or 503B outsourcing facilities .

Narrow, clinically-differentiated formulations can still exist, but the era of ordering copycat vials at a fraction of the price is closing; the nuance is in compounded GLP-1 versus labeled. This is a legal-status point rather than a lecture: it changes what is available and what a legitimate compounder can offer you, not whether you are allowed to manage your own care.

Living on it: muscle, food noise, alcohol, pregnancy

• Muscle loss is real, and protectable. Fast weight loss strips lean mass along with fat, and an appetite suppressant makes it easy to under-eat protein. Prioritize protein and lift; the how is in GLP-1 and muscle loss.
• The food noise going quiet is the point. Most people describe the constant background chatter about food fading, which is the mechanism doing its job, unpacked in what food noise is and why semaglutide quiets it.
• Alcohol often loses its pull. Many people report wanting to drink less on GLP-1 drugs, and the early evidence points the same way; see GLP-1 drugs and alcohol cravings.
• Pregnancy is a hard stop, and birth control can be affected. Semaglutide is not for use in pregnancy, and given its long half-life the guidance is to stop well before trying to conceive; it can also interact with how oral contraceptives are absorbed. The details, including the so-called Ozempic-baby stories, are in why Ozempic babies happen.

The bottom line

Wegovy works, on the order of 15 percent over two years, and the two things that surprise people are both predictable: the loss plateaus around month 15, and it comes back if you stop . Treat maintenance dosing as the plan, not a failure. The side effects are common but mostly mild and front-loaded on the dose ramp, so a slower climb is your best tool .

And know the field has moved: Wegovy is a solid, middle-of-the-pack option now, with tirzepatide, a 7.2 mg high dose, and an oral pill all in play, while the cheap compounded shortcut has largely closed . Pick the option that fits your body and your budget, then dose it competently.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 10 entries, mostly primary canon (the STEP 5, STEP 4, and STEP 1 extension trials, the Wegovy prescribing information, the SURMOUNT-5 head-to-head, and a semaglutide tolerability analysis), plus manufacturer and trade-press sources for the newest approvals, pricing, and compounding status, acknowledged inline as the weaker citations, last reviewed 2026-07-04.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Plateau analyzer overview - Public overview of the Pro plateau-pattern analyzer.

Frequently asked questions

How much weight will I lose on Wegovy?

On the standard 2.4 mg dose, mean weight loss was about 15 percent at two years in the STEP 5 trial, versus about 3 percent on placebo, and roughly a third of people lost 20 percent or more. That is an average, so individual results vary widely.

Why did my weight loss stall or plateau?

Because the drug works that way. In the trials, weight loss flattened out around week 60 and was then maintained rather than reversed. A stall near month 15 is the expected shape of the curve, not a sign you did something wrong.

What are the most common Wegovy side effects?

Gut side effects lead: nausea in about 44 percent, diarrhea 30 percent, vomiting 24 percent, and constipation 24 percent, all well above placebo. In the tolerability data about 98 percent of these were mild or moderate, they clustered during dose increases, and they faded with time.

Will I gain the weight back if I stop Wegovy?

Mostly, yes. A year after stopping 2.4 mg, people regained about two-thirds of what they had lost, and the average net loss fell from 17.3 percent to 5.6 percent. Continuing the drug is what keeps the weight off, so maintenance dosing is the plan.

Can I stay on a lower maintenance dose?

Yes. The label sanctions a maintenance dose of either 2.4 mg (recommended) or 1.7 mg once weekly. If 2.4 mg is hard to tolerate and 1.7 mg holds your weight, 1.7 mg is a legitimate place to stay.

Is Wegovy or Zepbound (tirzepatide) better for weight loss?

For raw weight loss, tirzepatide won the direct head-to-head. In SURMOUNT-5 it reached about 20.2 percent at 72 weeks versus about 13.7 percent for semaglutide, and more people hit the bigger milestones on tirzepatide.

Is there a Wegovy pill now?

Yes. An oral semaglutide 25 mg pill was FDA-approved in December 2025 for weight management, with about 16.6 percent loss in the best-case full-adherence analysis. It is needle-free but requires a strict empty-stomach dosing routine.

What should I do if I miss a Wegovy dose?

If your next scheduled dose is more than two days away, take the missed dose as soon as you can. If it is less than two days away, skip it and resume on your normal day. Do not double up.

Is compounded semaglutide still legal to buy?

Largely not, as a cheap ongoing option. The FDA declared the semaglutide shortage resolved in February 2025, and compounding a version that is essentially a copy of the approved drug is no longer permitted for 503A pharmacies or 503B facilities. Narrow, clinically-differentiated formulations can still exist.

How much does Wegovy cost without insurance?

The list price is around 1,349 dollars a month, but the maker's self-pay channel runs about 349 dollars a month for the pen, with a 199 dollar introductory price on the starter doses through the end of 2026. The high dose is about 399 dollars and the oral pill starts near 149 dollars.